MFDS Approves 'Omboju' for Ulcerative Colitis Treatment
Imported Pharmaceuticals by Hankook Lily
The Ministry of Food and Drug Safety announced on the 7th that it has approved 'Omboju 20mg/mL' (active ingredient: Mirikizumab), an ulcerative colitis treatment imported by Korea Lilly.
Ulcerative colitis is a chronic relapsing disease characterized by inflammation or ulcers in the colon.
According to the Ministry, this treatment is a monoclonal antibody drug that treats ulcerative colitis by inhibiting the downstream signaling of interleukin receptors that trigger inflammatory responses.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The Ministry explained that it is used to treat moderate to severe active ulcerative colitis in adults aged 18 and over who do not respond to standard treatments or biological agents, or who have no tolerance (the degree to which patients can endure side effects).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
